DICE
Price:
$47.55
Market Cap:
$2.27B
DICE Therapeutics, Inc., a biopharmaceutical company, builds various oral therapeutic candidates to treat chronic diseases in immunology and other therapeutic areas. Its platform DELSCAPE, is designed to discover selective oral small molecules to modulate protein-protein interactions (PPIs) as effectively as systemic biologics. The company's lead therapeutic candidate is DC-806, an oral antagonist of the pro-inflammatory signaling molecule, interleukin-17, which is a validated drug target implicated in a various immunology indications. It is also developing oral therapeutic candidates targeting a4ß7 integrin for the treatment of inflammatory bowel diseases, as well as targeting aVß1/aVß6 int...[Read more]
Industry
Biotechnology
IPO Date
2021-09-15
Stock Exchange
NASDAQ
Ticker
DICE
According to DICE Therapeutics, Inc.’s latest financial reports and current stock price. The company's current Enterprise Value is 2.21B. This represents a change of 73.49% compared to the average of 1.27B of the last 4 quarters.
The mean historical Enterprise Value of DICE Therapeutics, Inc. over the last ten years is 656.73M. The current 2.21B Enterprise Value has changed 33.55% with respect to the historical average. Over the past ten years (40 quarters), DICE's Enterprise Value was at its highest in in the June 2023 quarter at 2.14B. The Enterprise Value was at its lowest in in the September 2021 quarter at -61943558.00.
Average
656.73M
Median
789.19M
Minimum
200.01M
Maximum
848.54M
Discovering the peaks and valleys of DICE Therapeutics, Inc. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 290.57%
Maximum Annual Enterprise Value = 848.54M
Minimum Annual Increase = -74.91%
Minimum Annual Enterprise Value = 200.01M
Year | Enterprise Value | Change |
---|---|---|
2022 | 781.19M | 290.57% |
2021 | 200.01M | -74.91% |
2020 | 797.19M | -6.05% |
The current Enterprise Value of DICE Therapeutics, Inc. (DICE) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
592.80M
5-year avg
656.73M
10-year avg
656.73M
DICE Therapeutics, Inc.’s Enterprise Value is less than Nuvalent, Inc. (6.03B), less than Arcellx, Inc. (4.66B), less than Vaxcyte, Inc. (12.51B), greater than Viridian Therapeutics, Inc. (1.59B), greater than Ventyx Biosciences, Inc. (121.57M), greater than Immunocore Holdings plc (1.53B), less than Cytokinetics, Incorporated (6.69B), less than Edgewise Therapeutics, Inc. (3.11B), less than Karuna Therapeutics, Inc. (12.43B), less than Dyne Therapeutics, Inc. (2.25B), less than Chinook Therapeutics, Inc. (2.61B), greater than Pliant Therapeutics, Inc. (854.77M), less than Crinetics Pharmaceuticals, Inc. (4.74B), less than Ascendis Pharma A/S (6.99B), greater than Terns Pharmaceuticals, Inc. (509.09M), greater than Day One Biopharmaceuticals, Inc. (1.05B), greater than Acumen Pharmaceuticals, Inc. (134.49M), greater than Amylyx Pharmaceuticals, Inc. (315.53M), less than MoonLake Immunotherapeutics (2.53B),
Company | Enterprise Value | Market cap |
---|---|---|
6.03B | $6.11B | |
4.66B | $4.69B | |
12.51B | $13.01B | |
1.59B | $1.68B | |
121.57M | $151.23M | |
1.53B | $1.57B | |
6.69B | $6.09B | |
3.11B | $3.15B | |
12.43B | $12.60B | |
2.25B | $2.83B | |
2.61B | $2.71B | |
854.77M | $874.93M | |
4.74B | $4.99B | |
6.99B | $7.17B | |
509.09M | $600.34M | |
1.05B | $1.47B | |
134.49M | $174.23M | |
315.53M | $387.39M | |
2.53B | $2.87B |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like DICE Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like DICE Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the Enterprise Value?
How can you use the Enterprise Value?
What is DICE Therapeutics, Inc.'s Enterprise Value?
What is the highest Enterprise Value for DICE Therapeutics, Inc. (DICE)?
What is the 3-year average Enterprise Value for DICE Therapeutics, Inc. (DICE)?
What is the 5-year average Enterprise Value for DICE Therapeutics, Inc. (DICE)?
How does the current Enterprise Value for DICE Therapeutics, Inc. (DICE) compare to its historical average?